Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Liabilities: 2013-2024

Historic Other Non-Current Liabilities for Ocular Therapeutix (OCUL) over the last 8 years, with Dec 2024 value amounting to $13.2 million.

  • Ocular Therapeutix's Other Non-Current Liabilities rose 3.44% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 3.44%. This contributed to the annual value of $13.2 million for FY2024, which is 55.83% down from last year.
  • Ocular Therapeutix's Other Non-Current Liabilities amounted to $13.2 million in FY2024, which was down 55.83% from $30.0 million recorded in FY2023.
  • Ocular Therapeutix's Other Non-Current Liabilities' 5-year high stood at $98.3 million during FY2020, with a 5-year trough of $6.4 million in FY2022.
  • In the last 3 years, Ocular Therapeutix's Other Non-Current Liabilities had a median value of $13.2 million in 2024 and averaged $16.5 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Other Non-Current Liabilities skyrocketed by 710.90% in 2020, and later plummeted by 79.46% in 2021.
  • Ocular Therapeutix's Other Non-Current Liabilities (Yearly) stood at $98.3 million in 2020, then crashed by 79.46% to $20.2 million in 2021, then tumbled by 68.55% to $6.4 million in 2022, then surged by 372.16% to $30.0 million in 2023, then slumped by 55.83% to $13.2 million in 2024.